{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:56:29Z","timestamp":1785308189655,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.esmorw.2024.100065","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T05:25:10Z","timestamp":1724995510000},"page":"100065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Bridging research and practice: enhancing regulatory decisions with pragmatic clinical trials in oncology"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-0736","authenticated-orcid":false,"given":"M.D.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2267-6206","authenticated-orcid":false,"given":"A.E.","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-2024","authenticated-orcid":false,"given":"H.S.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"McKelvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.V.","family":"Sigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0586-3054","authenticated-orcid":false,"given":"J.D.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.esmorw.2024.100065_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0021-9681(67)90041-0","article-title":"Explanatory and pragmatic attitudes in therapeutical trials","volume":"20","author":"Schwartz","year":"1967","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.esmorw.2024.100065_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2147","article-title":"The PRECIS-2 tool: designing trials that are fit for purpose","volume":"350","author":"Loudon","year":"2015","journal-title":"BMJ"},{"issue":"33","key":"10.1016\/j.esmorw.2024.100065_bib4","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","volume":"35","author":"Kim","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmorw.2024.100065_bib5","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-Friends of Cancer Research Joint Research Statement","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100065_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cpt.2453","article-title":"The friends of cancer research real-world data collaboration pilot 2.0: methodological recommendations from oncology case studies","volume":"111","author":"Rivera","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"10.1016\/j.esmorw.2024.100065_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.22.00912","article-title":"Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-Lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100065_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/1078-0432.CCR-23-2690","article-title":"Novel approach to accelerate lung cancer research: Lung-MAP and the potential of public-private partnerships","volume":"30","author":"Herbst","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmorw.2024.100065_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8657","article-title":"SWOG S2302, PRAGMATICA-LUNG: a prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer","volume":"42","author":"Reckamp","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmorw.2024.100065_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00122","article-title":"Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"2018","author":"Mangat","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.esmorw.2024.100065_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_100040","article-title":"Pragmaticism in cancer clinical trials","volume":"44","author":"Sankar","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"36","key":"10.1016\/j.esmorw.2024.100065_bib16","doi-asserted-by":"crossref","first-page":"9275","DOI":"10.1200\/JCO.2004.00.0588","article-title":"Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials","volume":"23","author":"Mahoney","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.esmorw.2024.100065_bib17","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1200\/JCO.2010.29.6608","article-title":"Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications","volume":"28","author":"Kaiser","year":"2010","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T07:59:11Z","timestamp":1734163151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820124000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":12,"alternative-id":["S2949820124000432"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100065","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging research and practice: enhancing regulatory decisions with pragmatic clinical trials in oncology","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100065"}}